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Objectives: To compare the effectiveness of cranberry extract with low-dose trimethoprim in the
prevention of recurrent urinary tract infections (UTIs) in older women.
Patients and methods: One hundred and thirty-seven women with two or more antibiotic-treated UTIs
in the previous 12 months were randomized to receive either 500 mg of cranberry extract or 100 mg of
trimethoprim for 6 months. Trial registration: ISRCTN80031108.
Results: Thirty-nine of 137 participants (28%) had an antibiotic-treated UTI (25 in the cranberry group
and 14 in the trimethoprim group); difference in proportions relative risk 1.616 (95% CI: 0.93, 2.79) P 5
0.084. The time to ﬁrst recurrence of UTI was not signiﬁcantly different between the groups (P 5 0.100).
The median time to recurrence of UTI was 84.5 days for the cranberry group and 91 days for the tri-
methoprim group (U 5 166, P 5 0.479). There were 17/137 (12%) withdrawals from the study, 6/69 (9%)
from the cranberry group and 11/68 (16%) from the trimethoprim group (P 5 0.205), with a relative risk
of withdrawal from the cranberry group of 0.54 (95% CI: 0.19, 1.37).
Conclusions: Trimethoprim had a very limited advantage over cranberry extract in the prevention of
recurrent UTIs in older women and had more adverse effects. Our ﬁndings will allow older women with
recurrent UTIs to weigh up with their clinicians the inherent attractions of a cheap, natural product like
cranberry extract whose use does not carry the risk of antimicrobial resistance or super-infection with
Clostridium difﬁcile or fungi.
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Introduction
Urinary infection is the most common bacterial infection in
older people and recurrent urinary tract infection (UTI) is par-
ticularly common in older women. The current management of
recurrent UTI involves either repeated courses of antibiotics or
low-dose long-term antibiotic prophylaxis.
1 The evidence in
support of antibiotic prophylaxis is strong, with 11 placebo con-
trolled trials of which 10 show a signiﬁcant treatment beneﬁt.
1
In these trials, antibiotic prophylaxis was highly effective:
number needed to treat (NNT) to prevent one recurrence was
1.85, but side effects severe enough to stop treatment were
equally common (NNT for severe side effects was 1.58).
The main side effects measured in the trial were fungal super-in-
fection (oral or vaginal thrush) and gastrointestinal infections.
However, a growing reluctance to prescribe antibiotics is emer-
ging because of concerns about antimicrobial resistance and
other adverse effects on the normal bacterial ﬂora, such as
super-infection with Clostridium difﬁcile. At the same time,
there has been a resurgence of interest in the role of cranberry
products, stimulated by the conclusion of a Cochrane review that
‘there is some evidence from two good quality RCTs that
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over a 12 month period in younger women’ (mean ages 32 and
43 years).
2
The Cochrane review of antibiotic prophylaxis and SIGN
guideline 88 stated that a head-to-head trial of cranberry versus
low-dose antibiotic in the prevention of recurrent UTI was
required because previous placebo controlled trials had demon-
strated effectiveness for both, with the effectiveness of antibiotic
therapy being considerably superior.
2,3 While cranberry juice has
been studied in an underpowered trial of UTI prevention in 376
hospitalized older people,
4 there is a dearth of evidence concern-
ing its effectiveness in recurrent urinary infections in old age.
This is a surprising gap in the literature, given that UTI occurs
more frequently in old age than at any other time of life. In con-
trast, the literature on antibiotic prophylaxis does suggest that
this is likely to be effective in older women. Of the 11 trials
identiﬁed in the Cochrane review of antibiotic prophylaxis for
recurrent UTI, eight included post-menopausal women.
1 We
therefore designed a trial to compare the effectiveness and
acceptability of low-dose trimethoprim with cranberry products
in the prevention of recurrent UTI in older women. Trial
registration: ISRCTN80031108.
Methods
Study population
Inclusions: community dwelling women aged 45 years with at
least two antibiotic-treated UTIs or episodes of cystitis in the pre-
vious 12 months conﬁrmed by their general practitioner (GP) but
not necessarily conﬁrmed by microbiological culture. Participants
were recruited predominantly through the eastern node of the
Scottish Primary Care Research Network and also from responses to
an article in a local newspaper featuring the study.
Exclusions: previous urological surgery, stones or anatomical
abnormalities of the urinary tract; urinary catheter; diabetes melli-
tus; immunocompromised; pyelonephritis; severe renal impairment;
blood dyscrasias; symptomatic UTI at baseline; cognitive impair-
ment precluding informed consent; resident in institutional care; on
long-term antibiotic therapy; on warfarin therapy; regular cranberry
consumers; child bearing potential; unwilling to participate.
As a number of potential participants were occasional cranberry
consumers, it was decided that such individuals could participate
provided that there was a 2 week washout period prior to commen-
cing the study.
Written informed consent was obtained from participants and the
study was approved by the Tayside Committee on Medical Research
Ethics (06/S1402/23) and the MHRA (Eudract no: 2006-001313-15).
Randomization
Participants were randomized to receive either one capsule of
500 mg of cranberry extract (Cran-MaxTM; Buckton Scott Health
Products Ltd, UK) taken at bedtime for 6 months or one capsule of
100 mg of trimethoprim. Randomization was performed off-site by
DHP pharma in Powys, UK, which is an MHRA-approved manufac-
turing site. Randomization was performed in blocks of four using
Prisym PFW clin software to generate random numbers. Participants
were given a study number sequentially by the research nurses.
A copy of the treatment code was held by the Clinical Trials
Pharmacist in Ninewells Hospital, Dundee.
Cranberry product and trimethoprim preparation
DHP pharma over-encapsulated 100 mg trimethoprim tablets into
red size 00 capsules, and ﬁlled red size 00 capsules with 500 mg of
cranberry extract (Cran-MaxTM). Both sets of capsules were
identical in appearance.
Urine culture methods
A urine specimen was obtained at baseline from all participants and
cultured in the Medical Microbiology Laboratory using standard
protocols. Identiﬁcation and susceptibility testing on positive cul-
tures were performed by Vitek I (bioMe ´rieux) or Stokes’ suscepti-
bility testing and chromogenic agar for speciation of Escherichia
coli. Baseline results were not reported to clinical or research staff.
Specimens from participants who developed symptoms of UTI
during the trial were processed in the same way.
Outcome measures
Primary outcome
This was the proportion of participants in each group experiencing a
recurrence of an antibiotic-treated UTI and the time to ﬁrst recurrence.
Participants were censored (i.e. withdrawn from study partici-
pation) after their ﬁrst UTI. UTI was deﬁned as clinical symptoms
of dysuria and frequency in the absence of vaginal discharge with
or without microbiological conﬁrmation.
Secondary outcomes
Adherence. The participants were provided with two sealed tubs at
baseline each with 200 capsules containing either 100 mg of tri-
methoprim or 500 mg of cranberry extract. Adherence was assessed
by capsule counting at 3 and 6 months and expressed as the number
of capsules consumed divided by the number of capsules that
should have been consumed during the duration of each individual’s
period of study participation.
Adverse events and follow-up. After the baseline visit, further home
visits occurred at 3 and 6 months to re-check study eligibility,
record adverse events, check adherence and to note the courses of
antibiotics that had been prescribed for any indications. Participants
were telephoned at 1, 2, 4 and 5 months to encourage participation
and adherence, and to record any adverse events.
Statistical methods
Sample size. Based on the available literature, it was predicted that a
ﬁnal sample of 102 participants would be required to have 80%
power at P ¼ 0.05 of detecting a reduction in occurrences of urinary
infection from 16% in the cranberry group to 1% in the trimetho-
prim group.
5,6 In anticipation of a dropout rate of 15%, we intended
to recruit at least 120 participants.
Statistical analysis. Data were entered onto an Excel database and
then analysed using a Statistical Calculator v.2.06 (Mole Software,
Alpes de Haute-Provence 04230, France). Full statistical analysis
was completed prior to breaking the treatment code. Analysis was
by intention to treat. Time to ﬁrst recurrence of infection is pre-
sented as a Kaplan–Meier curve and differences between the groups
were assessed using the log-rank test.
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A total of 137 women were randomized, 69 to cranberry and 68
to trimethoprim (Figure 1).
There were no signiﬁcant differences between the groups at
baseline (Table 1).
Primary outcome
A total of 39/137 (28%) of participants had a symptomatic
antibiotic-treated UTI (25 in the cranberry group and 14 in the
trimethoprim group); the difference in proportions was relative
risk 1.616 (95% CI: 0.93, 2.79) P ¼ 0.084.
The time to ﬁrst recurrence of UTI was not signiﬁcantly
different between the groups [log-rank test: D ¼ 2.7, x2 (2.7, 1)
P ¼ 0.100].
The median time to recurrence of UTI was 84.5 days for the
cranberry group and 91 days for the trimethoprim group
(U ¼ 166, P ¼ 0.479).
Secondary outcomes
Withdrawals. There were 17/137 (12%) withdrawals from the
study, 6/69 (9%) from the cranberry group and 11/68 (16%) from
the trimethoprim group (P ¼ 0.205), with a relative risk of with-
drawal from the cranberry group of 0.54 (95% CI: 0.19, 1.37).
The reasons were as follows: for the cranberry group, gastro-
intestinal upset n ¼ 4; increased nocturia n ¼ 1; sensitive
swollen nipples n ¼ 1 and the trimethoprim group, gastrointesti-
nal upset n ¼ 4; itch/rash n ¼ 3; lost to follow-up n ¼ 2; restless
legs n ¼ 1; increased lethargy n ¼ 1. While gastrointestinal
upsets were equally common in both groups, itch/rash and loss to
follow-up occurred more commonly in the trimethoprim group.
Other adverse events. Other adverse events were similar
between the groups (Table 2).
Adherence. Adherence was good in both groups. Median (range)
adherence was 99 (25–149)% and 100 (66–112)% in the
cranberry and trimethoprim groups, respectively.
Assessed for eligibility by 16
GP practices n = 528
Responses from newspaper 
article n = 59
Declined participation 
n = 5
Did not meet inclusion   
criteria                 n = 26
No response n = 13
Declined participation
n = 163
Did not meet inclusion   
criteria n = 91
No response n = 152
137 consented and randomized
68 allocated to trimethoprim
Withdrawals           n = 11
Gastrointestinal n = 4
Itch/rash n = 3
Lost to follow-up n = 2
Restless legs n = 1
Increased lethargy n = 1
UTI n = 25 UTI n = 14 
Withdrawals n = 6
Gastrointestinal n = 4
Increased nocturia n = 1
Sensitive, swollen
nipples n = 1
69 allocated to cranberry
Completed 6 months
of treatment n = 38
Completed 6 months  
of treatment n = 43
Included in intention to treat
analysis n = 69
Included in intention to treat
analysis n = 68
Figure 1. CONSORT ﬂow chart.
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391Antibiotic use. A total of 15/69 (22%) participants in the
cranberry group and 17/68 (25%) in the trimethoprim group
were prescribed antibiotics for indications other than UTI during
their period of participation.
Causative organisms. For the 39 women who developed a
symptomatic UTI during the trial, the urine culture results
were as follows: E. coli,1 6( 9i nt h ec r a n b e r r yg r o u pa n d7
in the trimethoprim group); Klebsiella pneumoniae,3( 2i n
Table 1. Baseline characteristics
Variables Cranberry (n ¼ 69) Trimethoprim (n ¼ 68)
Age (years)
mean (SD) 62.6 (10.8) 63.3 (10.1)
range 45–93 46–88
Living circumstances
living alone 12 18
sheltered housing 1 7
Number of medications
median (range) 3 (0–13) 4 (0–11)
Length of history of UTIs (years)
median (range) 11 (1–50) 18 (1–53)
Number of self-reported UTIs in past 12 months
median (range) 3 (2–15) 3 (2–8)
Number of antibiotic-treated UTIs in past 12 months
a
median (range) 3 (2–15) 2 (2–8)
Bacteriuria at baseline 5/69 (7.2%) 7/68 (10.3%)
E. coli 26
K. pneumoniae 10
Streptococcus B 11
E. faecalis 10
aMann–Whitney U-test (P ¼ 0.72).
Table 2. Adverse events other than those resulting in withdrawal
Adverse event
n (%)
cranberry (n ¼ 69) trimethoprim (n ¼ 68)
Non-UTI urinary symptoms 12 (17) 9 (13)
Gastrointestinal upset 9 (13) 13 (19)
Thrush 3 (4) 3 (4)
Colds/ﬂu 4 (6) 4 (6)
Difﬁculty swallowing capsules/aftertaste/dry mouth 4 (6) 1 (1)
Exacerbation of back pain 4 (6) 2 (3)
Tiredness/lethargy 2 (3) 3 (4)
Itch/rash 2 (3) 2 (3)
Abdominal abscess 1 (1) 0
Breast carcinoma 1 (1) 0
Deterioration in bilateral vision 1 (1) 0
Vaginal dryness/atrophy 1 (1) 2 (3)
Falls 1 (1) 4 (6)
Shingles 0 1 (1)
Excessive thirst 0 1 (1)
Type II diabetes 0 1 (1)
Routine surgery 0 4 (6)
Migraine 0 1 (1)
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growth, 4 (2 in each group); mixed growth, 1 (in the cranberry
group); no signiﬁcant bacteriuria, 6 (4 in the cranberry group
and 2 in the trimethoprim group). No urine specimen was
obtained in 9 (7 in the cranberry group and 2 in the trimetho-
prim group).
Antibiotic resistance patterns. At baseline testing, 12 women
had positive urine cultures with 10
4 cfu/mL. Of these, 8 were
E. coli (6 susceptible to trimethoprim), 2 group B Streptococcus
(not tested against trimethoprim) and one each of K. pneumoniae
(trimethoprim-susceptible) and Enterococcus faecalis
(trimethoprim-resistant). Overall, therefore, 7/9 (78%) subjects
bacteriuric at baseline with Gram-negative bacteria had
trimethoprim-susceptible organisms.
Nineteen out of 39 (49%) women had symptomatic recur-
rences with positive urine cultures of 10
4 cfu/mL. All were
Gram-negative isolates. Of those with E. coli cultures, 11/16 were
trimethoprim-susceptible, and of those with K. pneumoniae,2 / 3
were trimethoprim-susceptible isolates. Thus, 13/19 of this sub-
group of participants had trimethoprim-susceptible isolates.
Discussion
Our head-to-head trial has shown that for older women with recur-
rent urinary infections, the 6 month risk of developing a UTI on
cranberry products is only 60% greater than that on low-dose tri-
methoprim; this difference was not statistically signiﬁcant.
Compared with cranberry extract, treatment with trimethoprim
conferred fewer than 7 additional UTI-free days. Our primary end-
point was symptomatic UTI treated by the GP. However, recur-
rence rates for microbiologically conﬁrmed symptomatic UTI were
also similar (16% for cranberry versus 12% for trimethoprim).
Validity of the trial
Our target of 120 participants for the trial was set to have 80%
power to detect a difference in effectiveness of 15% in risk of
recurrence between trimethoprim and cranberry, and assumed a
15% dropout rate. In fact we recruited 137 participants, of whom
17 (12%) withdrew but only two (1.5%) were lost to follow-up.
The remaining withdrawals were because of side effects, which
was one of the secondary outcomes for the trial. The participants
represented 29% of the 470 people who were screened and met
the inclusion criteria. Most participants were recruited by screen-
ing patient records from 16 GP practices, which is 20% of all the
practices in Tayside. The primary outcome was objective (ﬁrst
recurrence of clinical UTI treated by the GP) and could not be
inﬂuenced by the investigators. Moreover, participants and inves-
tigators were unaware of the participants’ treatment group until
the statistical analysis had been completed. Adherence to treat-
ment in our study was very good in both groups, which together
with the modest withdrawal rate lends further support to the
acceptability of encapsulated cranberry extracts.
2
The internal validity of the trial therefore seems good and we
also believe that the results should be applicable to other
primary care populations. Nonetheless, the trial result was not
what we expected. The literature had led us to predict that tri-
methoprim would prove considerably more effective, but only at
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Figure 2. Time to ﬁrst recurrence of UTI.
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393the expense of more adverse events. Withdrawals were indeed
higher in the trimethoprim group, but other adverse event rates
turned out to be low and remarkably similar between the groups.
Possible explanations
We have considered the possibility that neither treatment was
effective. At the design stage, we considered the inclusion of a
placebo group but rejected this option because Cochrane sys-
tematic reviews have concluded that both antibiotics and cran-
berry products are effective in preventing UTIs.
1,2 There is
uncertainty about how effective both treatments are in older
women, especially for cranberry but we did not consider that
this was sufﬁcient justiﬁcation for inclusion of a placebo
group. Moreover our eligibility criteria required two or more
antibiotic-treated UTIs in the previous 12 months so it was
reasonable to expect that without prophylaxis most women
would experience a recurrence within 6 months. It is therefore
unlikely that totally ineffective prophylaxis would have
allowed 81 (59%) of the 137 participants to have completed 6
months of treatment free of UTI recurrence.
We selected trimethoprim for antibiotic prophylaxis because
it is as effective as co-trimoxazole for treatment of UTI but has
fewer side effects.
7 Trimethoprim was included in one of the
placebo controlled clinical trials of antibiotic prophylaxis for
UTI and proved as effective as co-trimoxazole and nitrofuran-
toin.
6 Resistance to trimethoprim in bacteria causing UTIs has
increased in Northern European and American countries from
10% to 15% in the 1970s to 15% to 20% in the 1980s.
8 The
prevalence of trimethoprim resistance in the E. coli isolates
from our patients was 29%, which is only slightly higher than
the average resistance for all primary care isolates from mid-
stream urines in our laboratory (excluding catheter urine
samples) of 24% in 2004. Resistance has yet to reach a level
that should markedly reduce the effectiveness of trimethoprim in
lower UTI. The recurrence rate after treatment of symptomatic
lower UTI has been estimated for different levels of resistance
to co-trimoxazole.
9 At a resistance rate of zero, the recurrence
rate was estimated to be 5%, rising to 12% at 20% resistance
and 15% at 30% resistance.
9 These calculations assumed that
60% of women would respond to co-trimoxazole if their infec-
tion was caused by a resistant organism. In a recent UK study,
61% of women with lower UTI caused by trimethoprim-resistant
bacteria were symptom-free 1 week after trimethoprim treatment
and 58% were free of bacteriuria 1 month after treatment.
10 We
believe that trimethoprim prophylaxis should be effective at the
levels of resistance observed in our study and in the Tayside
population. It is possible that nitrofurantoin might have proved
more effective as resistance is less common; however, the evi-
dence suggests that it has more side effects.
1
We selected cranberry extract in preference to juice for our
study because previous work has shown equivalent efﬁcacy
between cranberry capsules (containing at least 1:30 parts con-
centrated juice) and cranberry juice.
11 Furthermore, cranberry
capsules have potential advantages over juice; capsules are more
convenient, cheaper (costs for 1 year of treatment are from £42
to £125 for cranberry tablets or capsules versus £175 to £257 for
cranberry juice) and may overcome compliance issues for some
individuals.
12 The high rates of withdrawal from some previous
studies suggest that cranberry juice may not be an acceptable
therapy over a long period of time.
Our power calculation estimated the difference in effect size
to be 15%. In our trial, the difference in effect size was 15%
(40% for cranberry versus 25% for trimethoprim), which was
not statistically signiﬁcant because the efﬁcacy of both treat-
ments was lower than we had predicted. We estimated that
recurrence with cranberry would be 16% to 20% and 1% to 5%
with antibiotics.
1,5,11 Our data regarding time to ﬁrst recurrence
suggest that the added beneﬁt to patients from antibiotics is
likely to be modest (Figure 2) and therefore that the value of
information from a larger trial in older women is unlikely to
justify the cost.
13
Conclusions
Our trial is the ﬁrst to evaluate cranberry in the prevention of
recurrent UTIs speciﬁcally in older women, and the ﬁrst
head-to-head double-blind comparison of cranberry versus anti-
biotic prophylaxis.
Trimethoprim had a very limited advantage over cranberry
extract in the prevention of recurrent UTIs in older women and
had more adverse effects. Our ﬁndings will allow older women
with recurrent UTIs to weigh up with their clinicians the
inherent attractions of a cheap, natural product like cranberry
extract whose use does not carry the risk of antimicrobial resist-
ance or super-infection with C. difﬁcile or fungi.
Further research is now required to discover if our ﬁndings
might apply to younger individuals with recurrent urinary
infections.
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